Evotec
Evotec SE, a leading global biotechnology company headquartered in Germany, is renowned for its innovative drug discovery and development solutions. Founded in 1993, Evotec has established a strong presence in Europe, North America, and Asia, focusing on areas such as central nervous system disorders, metabolic diseases, and oncology. The company offers a unique platform that integrates cutting-edge technologies and extensive expertise, enabling efficient and effective drug development processes. Notable achievements include strategic partnerships with major pharmaceutical firms, positioning Evotec as a key player in the biopharmaceutical industry. With a commitment to advancing healthcare, Evotec continues to drive progress in the development of novel therapeutics, making significant contributions to the global fight against disease.
DitchCarbon Score
How does Evotec's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Evotec's score of 91 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Evotec's reported carbon emissions
In 2024, Evotec SE reported total greenhouse gas emissions of approximately 300,670,000 kg CO2e, with emissions distributed across various scopes: 15,937,000 kg CO2e (Scope 1), 11,672,000 kg CO2e (Scope 2, market-based), and a significant 273,060,000 kg CO2e (Scope 3). The company has set ambitious targets to reduce its emissions, committing to a 50.4% reduction in absolute Scope 1 and 2 emissions by 2032 from a 2021 baseline. Additionally, Evotec aims to achieve a 72% reduction in Scope 3 emissions related to purchased goods and services and capital goods by the same year. Evotec's long-term goals include reaching net-zero greenhouse gas emissions across its value chain by 2045. This includes a further commitment to reduce absolute Scope 1 and 2 emissions by 95% by 2045 and Scope 3 emissions by 97% per million EUR value added within the same timeframe. The company also plans to increase its sourcing of renewable electricity from 25% in 2021 to 100% by 2026, maintaining this level through 2030. These targets align with the Science Based Targets initiative (SBTi) and reflect Evotec's commitment to sustainable practices within the pharmaceutical and biotechnology sector. The emissions data and reduction targets are not cascaded from any parent organization, indicating that they are independently reported by Evotec SE.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 28,000 | 00,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Evotec is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
